We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
- Authors
Laubach, J. P.; Mahindra, A.; Mitsiades, C. S.; Schlossman, R. L.; Munshi, N. C.; Ghobrial, I. M.; Carreau, N.; Hideshima, T.; Anderson, K. C.; Richardson, P. G.
- Abstract
Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.
- Subjects
MULTIPLE myeloma; B cell lymphoma; DRUG therapy; STEM cell transplantation; IMMUNOLOGICAL adjuvants; PATIENTS
- Publication
Leukemia (08876924), 2009, Vol 23, Issue 12, p2222
- ISSN
0887-6924
- Publication type
journal article
- DOI
10.1038/leu.2009.179